| Document |
Document Title |
|
WO/2019/023748A1 |
The present invention relates to a method of increasing fertility, or reducing rate of decline in fertility, or restoring fertility, of a female subject, comprising administering to the subject an effective amount of an agent which eleva...
|
|
WO/2019/023459A1 |
The present invention is directed to compounds of the formulae I, II and III as shown below (I) (II) (III) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the inven...
|
|
WO/2019/022158A1 |
Provided are a compound represented by formula I that can be used in nucleic acid photoreaction techniques, and a photoreactive crosslinking agent comprising the compound.
|
|
WO/2019/012080A1 |
The present disclosure relates to new nucleotide and oligonucleotide compounds and their use in nucleic acid sequencing applications. The compounds have formula (I) wherein B is a nucleoside base; and Fl is a fluorophore attached through...
|
|
WO/2019/012328A1 |
The present invention relates to combination therapies of a cytarabine conjugate and one or more anti-neoplastic agents for inhibiting cancer cell growth. In particular, the present invention relates to a conjugate of cytarabine and aspa...
|
|
WO/2018/041942A9 |
Embodiments of the invention are directed to new polymer linked multimeric guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being...
|
|
WO/2019/005898A1 |
Compositions and method are therefore disclosed for treating chronic obstructive pulmonary disease (COPD) and/or pulmonary fibrosis (PF). In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-c...
|
|
WO/2019/006455A1 |
Disclosed are P-stereogenic groups that may be used in the synthesis of compounds including stereochemically enriched P-stereogenic phosphorothioates. P-stereogenic groups may be provided in nucleoside phosphoramidites including a sugar ...
|
|
WO/2019/005901A1 |
Compositions and method are therefore disclosed for treating asthma. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting ...
|
|
WO/2019/002237A1 |
The present invention relates to the field of stereodefined phosphorothioate oligonucleotides and to stereodefining nucleoside monomers and methods of synthesis of stereodefined oligonucleotides using said monomer. Herein are disclosed o...
|
|
WO/2019/001292A1 |
A method for preparing a compound of formula T-3 according to route I is disclosed. The method comprises the following steps: a first step of reacting a compound of formula T-1 with a reagent comprising a PG group in the presence of an o...
|
|
WO/2019/005977A1 |
Disclosed herein, inter alia, are trioxolane compounds and methods of using the same for treatment and detection of diseases.
|
|
WO/2018/236814A2 |
The disclosure provides derivatives of both the oxidized form and the reduced form of nicotinamide riboside (NR) and nicotinic acid riboside (NAR). The NR and NAR derivatives have improved stability and bioavailability compared to NR and...
|
|
WO/2018/229493A2 |
The present invention generally relates to a process for the preparation of certain anticancer compounds as specific phosphate diastereoisomers.
|
|
WO/2018/229495A1 |
The present invention generally relates to a novel process for the preparation of 3'-deoxyadenosine derivatives,and particularly NUC-7738 (3'-deoxyadenosine-5'-O-[phenyl(benzyloxy-L-alaninyl)] phosphate) an anticancer ProTide of deoxyade...
|
|
WO/2018/229261A1 |
The invention relates to a prodrug compound consisting of a drug moiety comprising an amine or hydroxyl moiety and a protecting group moiety covalently linked to the amine or hydroxyl moiety. The drug moiety is effective in the treatment...
|
|
WO/2018/224822A1 |
The invention relates to tunicamycin analogues which are compounds according to Formula (I), or pharmaceutically acceptable salts thereof, (I) Wherein [Base] and R1 to R9 are as defined herein. The tunicamycin analogues are useful in the...
|
|
WO/2018/227168A1 |
Provided herein are nicotinamide adenine dinucleotide analogues, compositions comprising such compounds, and methods of using such analogues and compositions.
|
|
WO/2018/226930A1 |
A method performs expansion fluorescent in situ sequencing (ExSEQ) against a specific one or more target nucleic acids of interest. The method takes advantage of the isotropic expansion of swellable polymer matrices. Such swelling can be...
|
|
WO/2018/222774A1 |
Described herein are methods for treating and/or ameliorating a paramyxovirus infection, such as RSV, that include using compound (A), or a pharmaceutically acceptable salt thereof.
|
|
WO/2018/220376A1 |
The invention relates to microbubble complexes for use in methods of sonodynamic therapy which comprise a microbubble attached to or otherwise associated with one or more linking groups, each linking group being bound to at least one son...
|
|
WO/2018/213420A1 |
Provided herein are methods and compositions related to treating motor neuron diseases, such as ALS, in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside ...
|
|
WO/2018/212236A1 |
Provided is a novel oligonucleotide production method using a nucleoside or oligonucleotide that can be isolated easily and has high storage stability. An oligonucleotide production method including a coupling step of reacting a 5'-hydro...
|
|
WO/2018/208667A1 |
A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as induc...
|
|
WO/2018/207950A1 |
Provided are a novel class A GPCR antagonist, a production method for same, and a novel compound which interacts with the binding site of a class A GPCR Na+- water molecule cluster. A compound, or a salt thereof, having a structure in wh...
|
|
WO/2018/208727A1 |
Nucleoside and nucleotide compounds and analogues, and pharmaceutically acceptable compositions thereof, as inhibitors of CD73 for the treatment of diseases or disorders associated with CD73 activities, especially cancers, and methods of...
|
|
WO/2018/204784A1 |
Methods of minimizing hook effect interference in an immunoassay are disclosed. Also disclosed are reagents, kits, and immunoassay devices that may be utilized in accordance with the method.
|
|
WO/2018/203099A1 |
The present invention relates to a method for synthesizing diversely substituted purines starting from a pyrimidine. Formula (I). The method comprises the formation of an amidine group on the pyrimidine by implementing a Vilsmeier type r...
|
|
WO/2018/200357A1 |
Provided herein are methods and compositions related to treating and/or preventing infertility, improving fertility and/or increasing lactation in a subject by administering to the subject (e.g., orally administering to the subject) a co...
|
|
WO/2018/200356A1 |
Provided herein are methods and compositions related to treating and/or preventing kidney related diseases and disorders, treating and/or preventing acute kidney injury, and for improving kidney health in a subject by administering to th...
|
|
WO/2018/200859A1 |
Multitargeted pyrimidlne nucleoside carbamates, substituted with fluorine at both the base and the sugar moieties, are disclosed (see Formula I) where R =linear or branched alkyl (C1-7); R' = H, hydroxy protecting group; R" = H, phosphat...
|
|
WO/2018/199048A1 |
[Problem] To provide, in place of injected agents (nucleoside-based anticancer agents or antivirus agents) clinically used as therapeutic drugs for cancer or virus infections, a medicine that has high stability with respect to various hy...
|
|
WO/2018/194958A1 |
A method for determining in a sample, by mass spectrometry, the presence, absence, or amount of one or more analytes is described herein. The run time is less than six minutes. The method includes subjecting the sample to an ionization s...
|
|
WO/2018/192502A1 |
Provided in the present invention are an antiviral precursor drug nucleoside cyclophosphate compound based on liver-specific delivery (LSD) technology and the use thereof, and in particular, provided in the present invention are a compou...
|
|
WO/2018/189546A1 |
The present invention relates to chemical linkers and protecting groups, compounds and compositions containing the chemical linkers or protecting groups, and intermediates and processes that can be used to prepare them. The chemical link...
|
|
WO/2018/187540A1 |
The invention provides a compound of formula (I): wherein R is as described herein. The invention also provides a process for the preparation of the compound.
|
|
WO/2018/178679A1 |
The invention provides a combination comprising: (i) a compound of formula (Io) : (Io) or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims; and (ii) a co...
|
|
WO/2018/175436A1 |
Provided herein are methods for template-independent synthesis of oligonucleotides using a DNA polymerase. Also provided are methods for template-directed synthesis of oligonucleotides and for sequencing of nucleic acids using DNA polyme...
|
|
WO/2018/160088A1 |
The present invention relates to a prodrug and the use thereof to treat patients suffering from viral and cancerous diseases. The present prodrug provides inhibition of NS5B HCV polymerase, HBV DNA polymerase and HIV-1 reverse transcript...
|
|
WO/2018/160089A1 |
The present invention relates to a prodrug and to the use of same to treat the hepatitis C virus in patients. A prodrug of general formula 1, a stereoisomer thereof, an isotopically enriched analogue, a crystalline or polymorphic form.
|
|
WO/2018/155451A1 |
The purpose of the present invention is to provide: a nucleic acid compound represented by formula (I) or formula (II), said nucleic acid compound hardly forming a non-Watson-Crick base pair; and an oligonucleotide which comprises the nu...
|
|
WO/2018/152453A1 |
Provided herein are compounds useful for the treatment of cancer.
|
|
WO/2018/152450A1 |
Provided herein are compounds useful for the treatment of cancer.
|
|
WO/2018/149945A1 |
The present invention relates to a compound bearing at least two fucose moieties for its use as a drug in the prevention or treatment of infections caused by Aspergillus spp, said compound having a molecular weight comprised from 0.6 to ...
|
|
WO/2018/143403A1 |
Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce au...
|
|
WO/2018/144778A1 |
The disclosure relates to synthetic thermostable polynucleotides, as well as methods of synthesizing and delivering the polynucleotides.
|
|
WO/2018/144854A1 |
Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and thera...
|
|
WO/2018/144088A1 |
Disclosed is a therapeutic regimen which includes S-adenosyl methionine, or a salt thereof; folic acid, or a metabolite thereof, or a salt thereof; and a compound of Formula (I), or salt thereof, useful in the treatment of a variety of c...
|
|
WO/2018/138508A1 |
The invention relates to methods of synthesizing polymers, biopolymers, and nucleic acids, to immobilised dNTP/NTPs and kits comprising said immobilised dNTP/NTPs for use in said methods of nucleic acid synthesis.
|
|
WO/2018/140734A1 |
Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N 6-(4-hydroxybenzyl)adenosine and analogous compounds with amino acids or peptides. In one embodiment of the invention, ...
|
